- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Detrusor overactivity in patients unable to tolerate or unable to swallow oral oxybutynin
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 281KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 37KB)
Oxybutynin – November 2023
Oxybutynin: Transdermal patches 36 mg, 8; Oxytrol®
Last updated
1 March 2024